AXON Hires Silvia De Carvalho as New Clinical Studies Lead
De Carvalho will front AXON's clinical studies practice globally.
Former Klick Health Senior Vice President of Activation Strategy, Silvia De Carvalho, moves to front AXON’s clinical studies practice globally as clinical studies lead. She brings almost two decades of healthcare marketing expertise.
De Carvalho started her career working with the clinical development teams at Sanofi to identify optimal protocols and product viability in the diabetes landscape.
“Silvia is a wonderful addition to the AXON team, not only bringing a strong strategic mind to our client business, but also a high level of ambition for what we can achieve,” said Ralph Sutton, international managing partner of AXON, and its parent company AVENIR GLOBAL.
De Carvalho will help shape how AXON will support patients, caregivers, healthcare professionals, and broader stakeholders navigate the healthcare industry.
“Building on a great foundation, I am excited to continue our growth journey alongside our clients. A first key area of focus for us will be an expansion on our digital engagement services and how we can help clients optimally recruit and engage patients and healthcare professionals within digital and decentralized trials, but also effectively embrace adaptive trial design. The second area of focus will be helping clients to reach diverse patient populations to reflect the communities who may benefit from their medicines," said De Carvalho.
Reference
AXON HIRES SILVIA DE CARVALHO AS NEW CLINICAL STUDIES LEAD. (2023, July 17). AXON.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025
- IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
September 17th 2025
- Managing Background Therapies in the NIMBLE Phase III Trial
September 17th 2025
- Generative AI Transforms Clinical Study Report Development
September 16th 2025